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According to the Council for Medical Schemes Annual Report for 
2017/2018,[1] 16.08% of total benefits paid by medical schemes in 
2017 were for medicines. This high proportion of spend on medicines 
in the population with medical insurance in South Africa (SA) 
highlights the importance of medicine price regulation and the need 
for robust tools and policies to contain costs in order to manage 
resources. In 2005, the SA Minister of Health published a Government 
Gazette of regulations relating to a transparent pricing system for 
medicines and scheduled substances.[2] The Single Exit Price (SEP) 
legislation detailed in this Gazette aimed to regulate medicine pricing 
and remove the practice of discounts and rebates where benefits were 
not reaped by consumers.[3] When initially implemented, the SEP 
had a significant impact on the price of medicines and medicine 
expenditure, but over time a rebound in pricing was observed.[3] 
However, the SEP implementation was only intended to be the first 
phase of addressing medicine price concerns at the ex-manufacturer 
level.[3] To address the second phase, it was noted in the 2005 Gazette[2] 
that the Minister must publish in the Gazette a methodology for 
conforming to international benchmarks. In December 2006, the 
initial methodology for international benchmarking of the prices 
of medicines and scheduled substances in SA was published for 
comment.[4] In December 2010, a subsequent detailed proposed 
methodology addressing commentary was published for further 
comment.[3] In May 2014, the most recent proposed methodology for 
regulations relating to a transparent pricing system for medicines and 
scheduled substances (benchmark methodology) was published.[5]
 ‘The aim of international benchmarking, together with other 
regulatory interventions, is to:
 Protect the South African health system from paying distorted 
prices for medicines through the elimination of price distortions 
and price distorting behaviour.’[3] 
The Pricing Committee and the National Department of Health 
(NDoH) wish to establish a programme in SA that involves negotia-
ting drug prices that relate to the drugs’ therapeutic performance 
but also takes socioeconomic factors into account.[5] The proposed 
methodology for international benchmarking of medicines (IBM), 
referred to internationally as external reference pricing (ERP), 
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Background. External reference pricing (ERP) is an internationally applied pricing policy to regulate the price of medicines. In 2005, the 
South African (SA) Minister of Health published a Government Gazette of regulations relating to a transparent pricing system for medicines 
and scheduled substances, stating that the Minister must publish a methodology for conforming to international benchmarks. In May 2014, 
the most recent proposed benchmark methodology was published, detailing that international benchmarking of medicines (IBM) requires 
that the lowest price in a selected basket of countries (Australia, Canada, New Zealand, Spain and SA) be used as the ultimate price for the 
purposes of benchmarking of originator products.
Objectives. To provide a broad observational basis for the use of IBM and the proposed countries as a pricing tool; the feasibility of using 
BRICS countries (Brazil, Russia, India, China and SA) as comparator countries; and a small sample comparison of local state tender pricing 
in relation to the IBM proposed basket of comparator country pricing. Immunosuppressant medicines for organ transplant patients were 
used for this comparison, as they are relatively expensive and there is reluctance to implement pricing and reimbursement policy options 
to contain their costs.
Methods. Ex-manufacturer medicine pricing information for 2016, 2017 and 2018 was sourced for immunosuppressive medicines for SA 
(public and private sectors), Australia, New Zealand, Canada, Spain, Brazil and Russia. Unit prices were compared for products with the 
same international non-proprietary name (INN), strength, formulation and manufacturer. In most cases the products were matched on 
product name, bearing translation nuances in mind.
Results. Across all 3 years, in the majority of products, ERP using the proposed basket of comparator countries Australia, New Zealand, 
Canada and Spain lowered the local private sector ex-manufacturer price of medicine. Similarly, for the majority of products comparing 
local pricing with that of available BRICS country pricing data, the comparison lowered the price. For 92% of products where a comparison 
could be made, the SA state tender price was the lowest available price.
Conclusions. Conducting an ERP analysis consumes time and resources. However, it may prove to reduce a current or proposed medicine 
price and may be considered as one of a range of medicine pricing policies employed by a country. It should not be used in isolation from 
other medicine pricing and reimbursement policies.
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requires that the lowest price in a selected basket of countries 
be used as the ultimate price for the purposes of benchmarking. 
The selected basket of countries includes Australia, Canada, New 
Zealand, Spain and SA.[5] The NDoH may review the basket every 
2 years and a possible complementary list of benchmark countries 
may be published online.[5] The proposed methodology includes 
two protections against the potential for inappropriate reductions 
of prevailing prices at implementation.[5] These are an exemption 
application process and a phased approach that will delay the 
implementation of the ultimate benchmark by 2 years. The first phase 
of the phased approach will set the benchmark at the average of prices 
in the proposed country basket, and the second phase will implement 
the ultimate benchmark of the lowest price in the proposed country 
basket.[5] This most recent proposed methodology was published 
in 2014, and no subsequent proposed changes or final benchmark 
methodologies have been published. Applicants are not prevented 
from complying with the proposed methodology in the interim.[5]
Evidence regarding the impact of different pricing policies on 
medicine prices is scarce, especially in low-income countries. This 
issue is twofold, as it refers not only to a lack of evidence but also 
a potential lack of successful pricing policy implementation.[6,7] 
Literature assessing whether medicine prices would be lowered on 
implementation of this IBM/ERP policy is lacking.
Furthermore, the current proposed basket of countries was 
chosen on the basis of prespecified criteria selecting countries with 
effective systems for pricing and regulating medicines.[3] However, 
their health system structure and socioeconomic background may 
be significantly different from that of SA. A major factor that 
contributed to the resultant proposed list of benchmark countries 
was accessibility to pricing data.[5] As emerging economies, BRICS 
countries (Brazil, Russia, India, China and SA) may appear to be 
more suitable economic comparators, but a thorough economic 
analysis would be required to ascertain economic comparability if 
that was a primary reason for inclusion. The aim of the co-operation 
among the BRICS countries is non-competitive, sustainable, 
equitable and mutually beneficial development, and at the BRICS 
meeting of health ministers in July 2018, access to medicines 
was one of the five key topics discussed.[8] This collaboration 
may therefore facilitate access to transparent pricing information, 
including unpublished confidential discounts on listed prices, 
among BRICS medicine agencies.
The SA state sector is currently not subject to the SEP legislation 
and makes use of tender processes to procure medicines by means of 
volume-based purchasing.[9] A secondary analysis aimed to provide 
insight into whether state tender prices remain consistently low when 
compared with private sector SA medicine prices and the proposed 
basket of comparator countries.
Objectives
The purpose of this observational analysis was to determine whether 
implementation of the proposed methodology for IBM would have 
a positive (cost-saving) impact on the prices of immunosuppressive 
medicines for transplant patients. The primary comparison aimed 
to assess whether the application of IBM with the proposed basket 
of comparator countries would lower the price of medicines locally. 
The secondary analysis aimed to assess whether using BRICS 
countries as a benchmark would lower the local price of medicine. 
Furthermore, a comparison of SA government sector tender prices 
with the five proposed comparator countries (SA private sector, 
Australia, Canada, New Zealand, Spain) aimed to assess whether 
state tender prices are the lowest.
Internal reference pricing as a cost-minimisation tool may not be 
considered a feasible instrument to implement for this particular 
group of medicines, but international benchmarking may provide 
an alternative mechanism to lower the cost of medicines in this 
group in a manner that does not directly involve the person using 
the medicine.
Overall, the objectives of this study were to provide a broad 
observational basis for the use of IBM and the proposed countries as 
a pricing tool, the feasibility of using BRICS countries as comparator 
countries, and a small sample comparison of local state tender pricing 
in relation to the pricing from the proposed basket of comparator 
countries.
Methods
Ethical clearance was obtained from the University of KwaZulu-Natal 
(ref. no. HSS/0154/013).
Selection of medicines
Immunosuppressants used to prevent graft rejection were selected 
from Anatomical Therapeutic Classification (ATC) class L04A – 
Immunosuppressants. As this list is exhaustive and not exclusive to 
medicines used to prevent graft rejection, local and international 
registration status was determined to isolate the international non-
proprietary name (INN) products used in this setting. Products 
registered locally or by the US Food and Drug Administration or 
the European Medicines Agency were included in the list for the 
sourcing of pricing information.
Equine gamma globulin (Atgam) is classified under the ATC 
group L04AA and is registered for acute use in renal transplant 
rejection. This acute use differs from the long-term prophylactic 
nature of the other immunosuppressants included for comparison 
from L04A; however, as the list of products for comparison was 
already small, further exclusion due to duration and setting of use 
was not enforced.
Time frame of medicine pricing information
An attempt to obtain pricing information for 2016, 2017 and 2018 
for all comparator countries was made. This was successful with the 
exception of Spain, despite repeated attempts to obtain historical 
pricing information (2016 and 2017) from the Spanish authorities 
and academics in that country.
Data sources
In accordance with the specifications of the Gazette methodology, the 
ex-manufacturer prices of the comparator countries were sourced. 
Publicly available online sources of ex-manufacturer pricing were 
obtained for Australia, Canada, New Zealand, Spain, SA (private 
sector ex-manufacturer and state tender), Brazil and Russia. Prices 
for Australia were obtained online from the Pharmaceutical Benefit 
Scheme,[10] for Canada from the Alberta Drug Benefit List,[11] for 
New Zealand from the PHARMAC online schedule,[12] and from the 
Spanish Ministry of Health, Consumer Affairs and Social Welfare.[13]
It was assumed that the ex-manufacturer or ex-factory price should 
be devoid of any mark-ups and inclusion of VAT; however, where the 
published prices were not explicitly ex-factory prices, details have 
been provided as to how the ex-factory prices were calculated or 
confirmed.
The National Pharmaceutical Pricing Authority of the Government 
of India provides an online public pricing resource of scheduled 
formulations,[14] but as the price is regulated at the maximum retail 
price and that is the published price, no public resource of regulated 
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ex-manufacturer pricing was found. A resource of state tender 
pricing was also found, but would not be an appropriate comparator 
for this benchmarking analysis.[15]
Although reform of the price setting of medicine in China is 
underway,[16] no formal publicly available resource of medicine 
pricing was found. The China Drug and Food Administration drug 
database does not include pricing.[17]
An online appendix with detailed information on how ex-factory 
prices were obtained from the online resources is available (http://
samj.org.za/public/sup/online_appendix.docx).
Pricing
In line with the Gazette methodology, medicine prices were converted 
to South African rands (ZAR) using the average currency exchange 
rate for the particular currency for the past 12 months. Historical 
exchange rate data were obtained from the South African Reserve 
Bank website.[18] The time ranges of historical data exported were for 
1 January 2016 - 31 December 2016, 1 January 2017 - 31 December 
2017, and 1 June 2017 - 31 May 2018. The ranges were exported in 
Excel 2013 (Microsoft, USA) and an average conversion rate for the 
time range was calculated in Excel.
Sorting process
Data lines were matched on the basis of the same INN, strength, 
formulation and manufacturer. In most cases the products were 
matched on product name, bearing in mind translation nuances. 
Where products were matched on all the listed criteria but the trade 
name varied (e.g Mycocept and Mycophenolate Sandoz), they were 
still grouped together. Different pack sizes were included in the same 
group and in all cases pricing was compared on unit price level. 
Generic products were not excluded; however, only products where 
SA private sector pricing was available were assessed.
The Government Gazette 37625 Regulations relating to a 
transparent pricing system for medicines and scheduled substances 
(benchmark methodology) published in May 2014[5] state that the 
IBM methodology will apply to all originator medicines for which 
there are fewer than two generic competitors. On completion of 
this phase of implementation, it is the intention of the Minister of 
Health to address the methodology for originator medicines with 
two or more generic competitors and generic medicines. For the 
purposes of this analysis, products were not included or excluded 
on this basis.
Assessment of products
Products were analysed per year using six key questions: 
A.   Would benchmarking against the four countries listed in 
the proposed basket of comparator countries (Australia, New 
Zealand, Canada and Spain) decrease the SA medicine price? For 
how many products did benchmarking against these countries 
lower the price?
B.   Is the full benchmarking basket available (Australia, New Zealand, 
Canada and Spain)?
C.   Which benchmarking country has the lowest price (by frequency)?
D.   Would benchmarking against the remaining BRICS countries 
decrease the SA medicine price?
E.   Which BRICS country has the lowest price (by frequency)?
F.    Is the state tender pricing lower than all countries in the proposed 
basket of comparator countries, and for products where state 
tender prices are available, for how many products was the state 
tender price the lowest price compared with the proposed basket 
of comparator countries?
Results
Pricing information was sourced for products containing ciclo-
sporin, mycophenolate mofetil, mycophenolic acid, sirolimus, 
tacrolimus, everolimus, azathioprine and equine gamma globulin.
Table 1 presents a summary of the results. Using pricing data 
from 2016, 2017 and 2018, a total of 78 IBM immunosuppressant 
products were analysed in accordance with the proposed ultimate 
IBM methodology stipulating that the lowest price in the proposed 
comparator countries (including SA) must become the benchmark 
price. Owing to a more limited number of appropriate product 
pricing matches, a smaller number of products, 66, were analysed 
using the same methodology but with BRICS countries as 
comparators. The application of the IBM methodology lowered the 
SA private sector ex-manufacturer price in 68%, 85% and 85% of 
products in 2016, 2017 and 2018, respectively. In only one product 
across all three years was the full benchmarking set of country data 
available, and for that product, Spain had the lowest price listed 
(Pfizer Rapamune sirolimus 1 mg tablet). Australia consistently 
had the highest frequency of the lowest price; however, where New 
Zealand pricing was available it demonstrated the largest average 
percentage decrease of price by a benchmarking country consistently 
in 2016 (60%), 2017 (53%) and 2018 (56%).
Looking at the BRICS countries, ex-manufacturer pricing data 
were obtained for Brazil and Russia. By comparison against these two 
countries, the SA private sector ex-manufacturer price was lowered 
in 81%, 90% and 81% of products where a comparator price was 
available in 2016, 2017 and 2018, respectively. In the majority of 
products in 2016, 2017 and 2018, Russia had the highest frequency 
of the lowest price.
Where an SA state tender price was available for a product, it was 
compared with the proposed basket of comparator countries where 
available, including the SA private sector ex-manufacturer price; 
38 products were assessed for this comparison. In each year, in 92% 
of products where a comparison could be made, the SA state tender 
price was the lowest available price.
Table 2 presents a summary of the medicine products assessed for 
each comparison. In all 3 years the originator products that included 
only BRICS comparators were Novartis Simulect (basilixmab) 20 mg 
vial and Astellas Prograf (tacrolimus) 5 mg/mL 1 mL injection.
Discussion
This observational analysis of immunosuppressant medicines 
showed that for the majority of products, ERP using the proposed 
basket of comparator countries Australia, New Zealand, Canada and 
Spain lowered the price of the medicine. Similarly, for the majority 
of products comparing local pricing with that of available BRICS 
country pricing data, the comparison lowered the local private sector 
ex-manufacturer price of medicine.
Historical information for Spanish medicine pricing was not 
available, so only pricing for 2018 was available for capturing and 
comparison. The 2018 comparison for Pfizer’s Rapamune (sirolimus) 
1 mg tablets was the only case in which information was available 
for all five proposed comparator countries including Australia, 
New Zealand, Canada, Spain, and of course SA. Most products 
had pricing for SA and two other reference price countries. Most 
frequently, Australia had the lowest price in the proposed basket 
of comparator countries; however, where available, New Zealand 
pricing consistently demonstrated the largest average percentage 
decrease of price (average decrease of 56% in 20 products).
The proposed benchmarking methodology Gazette published in 
2010[3] provides thorough detail on the selection criteria applied to 
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the proposed basket of comparator countries. Of the 30 countries 
listed in the summary table, only Spain, Canada, New Zealand and 
Australia met all criteria (i.e. Pharmaceutical Inspection Co-operation 
Scheme member, signatory of the Agreement on Trade-Related 
Aspects of Intellectual Property Rights, use of pharmacoeconomic 
evaluations, internal and ERP, public spend >60% of total health 
expenditure), and these were the only countries with access to 
pricing information. Belgium, Hungary, The Netherlands, Poland 
and Portugal met the criteria with the exception of access to 
pricing data.[3] The methodology proposed that only Organisation 
for Economic Cooperation and Development (OECD) countries 
should be evaluated for inclusion in the basket, one of the reasons 
being that the OECD would facilitate sharing of information and 
policy experiences.[3] The lack of accessible and transparent pricing 
data is an obvious limiting factor. Although BRICS countries were 
not evaluated for inclusion in the proposed basket of comparator 
countries,[3] the aim of including them as a separate assessment was 
to compare pricing in leading emerging markets where the aim of 
co-operation among the countries is non-competitive, sustainable, 
equitable and mutually beneficial development.[8] This analysis was 
limited by the availability of regulated medicine pricing information 
in India and China. Information for current and historical Brazilian 
medicine pricing was freely and clearly accessible online and could 
be translated from Portuguese to English using Google Translate. 
Similarly, Russian online medicine pricing information also required 
the use of Google Translate. However, the added complication of 
a different alphabet made this translation less intuitive, and the 
identification of appropriate comparator pricing information more 
tedious, than with the Brazilian comparison. Among the three 
BRICS countries included in the analysis, Russian pricing was most 
frequently the lowest. Although the use of Russia as a comparator 
country for SA may appear favourable on the basis of this analysis, 
results should be used with caution as attempts to verify pricing 
information with the Russian State Register of Medicines were not 
successful. A concern is that the pricing information may be out of 
date and not a true reflection of the actual current ex-manufacturer 
pricing in Russia.
SA state tender pricing information was not available for all 
proposed comparator products, but where it was, it had the lowest 
price in 92% of products (n=38). The difference observed between SA 
private sector ex-manufacturer medicine pricing and SA state sector 
pricing is driven by volume-based pricing negotiations in the form 
of state tenders.[9] This assessment, although limited by sample size, 
should prompt discussion around the possibility that ERP in isolation 
Table 1. Summary of results* 
  2016 2017 2018
IBM benchmarking products, n  25 27 26
A Products where the proposed basket lowered price, n 17 23 22
Products where the proposed basket lowered price, % 68 85 85
B Full benchmarking country set, n 0 0 1
Products with 3/4 countries plus SA, n 7 7 9
Products with 2/4 countries plus SA, n 13 16 14
Products with 1/4 countries plus SA, n 5 4 2
Products with no price change (SA lowest), n 8 4 4
Products with no price change, % 32 15 15
C Lowest-priced country by frequency, n
Australia 11 14 12
New Zealand 6 8 8
SA 7 4 4
Canada 1 1 1
Spain 0 0 1
BRICS products, n 21 21 21
D Price lowered by comparator countries, n 17 19 17
Products where BRICS comparator lowered price, % 81 90 81
E Lowest-priced country frequency, n
Russia 13 18 16
Brazil 4 1 2
SA 4 2 3
F In products where state tender prices are available, n products available 13 13 12
In how many products were state tender prices the lowest price compared with 
all 5 proposed benchmark countries incl. SA, n
12 12 11
Products where the SA state tender price was the lowest price compared with all 
5 proposed benchmark countries incl. SA, %
92 92 92
Average decrease per country, % (in products where decrease seen)
Australia 27 (n=11) 35 (n=14) 37 (n=12)
New Zealand 60 (n=6) 53 (n=6) 56 (n=8)
Canada 2 (n=1) 16 (n=1) 18 (n=1)
Spain n=0 n=0 30 (n=1)
SA = South Africa; BRICS = Brazil, Russia, India, China and SA.
*For the six key questions A - F, see text.
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may not generate as favourable medicine pricing as would either 
volume-based pricing or a combination of the two policies.
Although limited by small sample size and ATC, this analysis 
has shown that IBM using Australia, New Zealand, Canada and 
Spain would lower the price of the majority of medicines in 
this immunosuppressant analysis. It is important to explore why 
these comparator countries may be generating more favourable 
medicine pricing than the private sector in SA. Spain, Australia 
and New Zealand all include a form of internal reference pricing in 
their national reimbursement policies, and although Canada does 
not directly regulate off-patent originator and generic pricing,[3] 
outpatient prescriptions are reimbursed by private insurers who may 
decide to employ a form of internal reference pricing. Although the 
use of generic reference pricing of immunosuppressant medicines in 
transplant recipients is a complex issue, and where implemented may 
be done with tight controls to avoid switching among products,[19] the 
use of internal reference pricing by comparator countries does once 
again highlight the importance of a multidimensional approach to 
the pricing of medicines in general.
Noted challenges of the observational analysis included access and 
availability of current and historical pricing data, comprehension of 
the data available and their applicability within the context of the 
specific country, and the matching of products for comparison. The 
medicine pricing information from a comparator country may be 
meaningless if it is not used with an understanding of the pricing and 
reimbursement policies, taxation structures and healthcare funding 
employed in that specific country. In addition, a medicine’s price 
has a specific local history that affects pricing and includes patent 
expiry timing and the subsequent launch of competitor generics 
on the market. Medicine prices may be compared across countries 
at a specific point in time when on- and off-patent market factors 
may differ. Similarly, the emergence of negotiated confidential 
discounts and pricing for patient access schemes may affect the 
transparency of the published medicine pricing and its use in 
an ERP comparison. The Gazette methodology explicitly details 
how products should be grouped for comparison;[2-5] however, the 
reality of the application of this methodology is a challenge and 
often requires further investigation and occasionally a degree of 
assumption. For example, a product may match on most factors 
including trade name, manufacturer and strength, but the publicly 
available medicine pricing database of one country may list the 
formulation as a tablet and another country may list it as a film-
coated tablet. Furthermore, the complex nature of the pharmaceutical 
industry, involving mergers, local marketing or distribution licences, 
may also complicate confirmation of the same manufacturer source.
The main limitation of this observational analysis is the small 
sample size and restriction to one therapeutic medicine group, 
immunosuppressants for organ transplant rejection. The analysis 
did not attempt to ascertain whether the local registered price of 
the medicine was already subject to the proposed benchmarking 
methodology and whether this may have contributed to the reason 
why SA had the lowest price for certain products. Although applicants 
may already comply, it must be noted that the benchmarking 
methodology remains in proposal form and has yet to be formally 
implemented. This factor may complicate future analyses assessing 
the impact that formal implementation has on local drug prices.
Since the commencement of this observational analysis, the 
Euripid Collaboration and the EU Health Programme have published 
12 guiding principles for ERP. In July 2018 they published these 
12 principles in a guidance document with the aim of ‘coordinating 
approach of national authorities regarding the use of ERP to avoid/
mitigate negative impact for patient access to medicines’.[20] Although 
this document has been developed in a European context, the 
principles should be considered by any country considering or 
revising an international benchmarking policy.
Conclusions
ERP is an internationally applied pricing policy used to regulate the 
price of medicines and should be formally implemented locally. It 
should not be used in isolation from other medicine pricing and 
reimbursement policies.[20] As can be seen in this analysis, both the 
use of ERP and comparison with the price derived from volume-
based pricing in the form of state tenders have the potential to 
lower the local cost of medicine in the private sector. Even with a 
shift to a National Health Insurance system, IBM may provide a 
valuable component within the broader framework of medicine price 
regulation. Most countries, even those with social health insurance 
systems, apply a combination of regulatory tools.[3] Denmark, Spain, 
Canada and France are examples of countries that have used a 
combination including, but not limited to, pharmacoeconomic 
guidelines and IBM.[3]
High-quality evidence on the long-term effects of pricing policies 
is limited. Where evidence on the impact of ERP is available, 
it is limited to country or European experience or an isolated 
medicine class comparison, which limits the external validity of the 
observations.
Conducting an ERP analysis, even of one product, consumes time 
and resources. However, as shown in this small analysis, it may prove 
to reduce a current or proposed medicine price. It may also provide 
an opportunity for reflection on how comparator countries are 
approaching medicine pricing and provide insights for constant local 
improvement and dynamic medicine pricing policies.
Published medicine pricing information should be updated at 
regular intervals, clearly stipulate the points at which the medicine 
price is regulated within the local context, and clarify the applicable 
taxes that are included or would be added to the published medicine 
price. Resources should clearly state to which sector the published 
medicine pricing information applies. This case study is in favour of 
the proposed benchmarking basket, but as more countries begin to 
publish medicine pricing information online, the SA basket should be 
regularly reviewed in order to potentially expand the list of included 
reference countries.
The common key health focus area of medicine access and the 
connection among the BRICS countries may facilitate information 
sharing. The comparison with Russian list prices was favourable, but 
without formal validation of the prices it is not recommended for 
inclusion in the basket. Brazil’s pricing was often higher than SA’s in 
the analysis, but there were examples where it was lower. A broader 
analysis across medicine classes should be conducted to further assess 
how pricing compares between SA and Brazil.
Collaboration between countries to share pricing resources and 
enhance the benefit derived from ERP methodologies and other 
pricing policies should be promoted to facilitate improved access to 
medicine.
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